Cargando…
Cell-free DNA and circulating TERT promoter mutation for disease monitoring in newly-diagnosed glioblastoma
The clinical implications of plasmatic cell-free and tumor DNA (cfDNA and ctDNA) are challenging in glioblastoma. This prospective study included 52 consecutive newly diagnosed glioblastoma (n = 49) or gliosarcoma (n = 3) patients treated with concomitant temozolomide and radiotherapy (RT-TMZ), foll...
Autores principales: | Fontanilles, Maxime, Marguet, Florent, Beaussire, Ludivine, Magne, Nicolas, Pépin, Louis-Ferdinand, Alexandru, Cristina, Tennevet, Isabelle, Hanzen, Chantal, Langlois, Olivier, Jardin, Fabrice, Laquerrière, Annie, Sarafan-Vasseur, Nasrin, Di Fiore, Fréderic, Clatot, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7641818/ https://www.ncbi.nlm.nih.gov/pubmed/33148330 http://dx.doi.org/10.1186/s40478-020-01057-7 |
Ejemplares similares
-
Simultaneous detection of EGFR amplification and EGFRvIII variant using digital PCR-based method in glioblastoma
por: Fontanilles, Maxime, et al.
Publicado: (2020) -
Impact of EGFR(A289T/V) mutation on relapse pattern in glioblastoma
por: Noeuveglise, A., et al.
Publicado: (2022) -
TERT Promoter Alterations in Glioblastoma: A Systematic Review
por: Olympios, Nathalie, et al.
Publicado: (2021) -
Circulating ESR1 mutations at the end of aromatase inhibitor adjuvant treatment and after relapse in breast cancer patients
por: Allouchery, Violette, et al.
Publicado: (2018) -
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer
por: Clatot, Florian, et al.
Publicado: (2020)